Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses

Blood

Volumn 118, Issue 12, 2011, Pages 3195-3204

  Karube, Kennosuke ^a   Nakagawa, Masao ^a   Tsuzuki, Shinobu ^a   Takeuchi, Ichiro ^b   Honma, Keiichiro ^a   Nakashima, Yasuhiro ^a,c   Shimizu, Norio ^d   Ko, Young Hyeh ^e   Morishima, Yasuo ^a   Ohshima, Koichi ^f   Nakamura, Shigeo ^g   Seto, Masao ^a,h  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^c ASO IIZUKA HOSPITAL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NAGOYA UNIVERSITY HOSPITAL   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A20 GENE; AIM1 GENE; ARTICLE; ATG5 GENE; CELL LINE; CELL PROLIFERATION; CHROMOSOME 6Q; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; FOX03 GENE; FUNCTIONAL GENOMICS; GENE CONTROL; GENE DELETION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC TRANSDUCTION; GENOMICS; HACE1 GENE; HUMAN; HUMAN CELL; LACE1 GENE; MOLECULAR PATHOLOGY; NK T CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POPDC3 GENE; PRDM1 GENE; PREP GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 80053121023     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-346890     Document Type: Article

References (51)

1. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2009:285-288.
2. Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggressive NK-cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2009:276-277.
3. Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/ leukaemia. Br J Haematol. 1997;98(4):922-926. (Pubitemid 27421636)
4. Wong KF, Zhang YM, Chan JK. Cytogenetic abnormalities in natural killer cell lymphoma/ leukaemia - is there a consistent pattern? Leuk Lymphoma. 1999;34(3-4):241-250. (Pubitemid 29385167)
5. Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol. 2000; 157(6):1803-1809.
6. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155(5):1419-1425.
7. Huang Y, De Reynies A, De Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226-1237.
8. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23(6):1139-1151.
9. Nakashima Y, Tagawa H, Suzuki R, et al. Genome- wide array-based comparative genomic hybridization of natural killer cell lymphoma/ leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/ T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44(3):247-255. (Pubitemid 41397093)
10. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454(7201):226-231. (Pubitemid 351969894)
11. Ngo VN, Davis RE, Lamy L, et al.Aloss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441(7089):106-110.
12. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-1679. (Pubitemid 351432507)
13. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114(15):3265-3275.
14. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106(5):1770-1777. (Pubitemid 41208593)
15. Van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. (Pubitemid 38072572)
16. Tsuchiyama J, Yoshino T, Mori M, et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood. 1998;92(4):1374-1383. (Pubitemid 28369051)
17. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001;97(3): 708-713. (Pubitemid 32113404)
18. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652-658. (Pubitemid 24133034)
19. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996; 24(3):406-415. (Pubitemid 26098857)
20. Kagami Y, Nakamura S, Suzuki R, et al. Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus. Br J Haematol. 1998;103(3):669-677. (Pubitemid 28545300)
21. Yagita M, Huang CL, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14(5): 922-930. (Pubitemid 30235072)
22. Zhang Y, Nagata H, Ikeuchi T, et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol. 2003;121(5):805-814. (Pubitemid 36718199)
23. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64(9):3087-3095. (Pubitemid 38581408)
24. Lipson D,Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol. 2006; 13(2):215-228.
25. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)
26. Kim WS, Honma K, Karnan S, et al. Genomewide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosomes Cancer. 2007;46(8):776-783. (Pubitemid 46912348)
27. Watkins WJ, Umbers AJ, Woad KJ, et al. Mutational screening of FOXO3A and FOXO1A in women with premature ovarian failure. Fertil Steril. 2006;86(5):1518-1521. (Pubitemid 44602042)
28. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203(2):311-317. (Pubitemid 43290840)
29. Izumiyama K, Nakagawa M, Yonezumi M, et al. Stability and subcellular localization of API2- MALT1 chimeric protein involved in t(11;18) (q21; q21) MALT lymphoma. Oncogene. 2003;22(50): 8085-8092. (Pubitemid 37487299)
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139(2):271-279.
31. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009;114(12):2467-2475.
32. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009; 459(7247):712-716.
33. Zhang L, Anglesio MS, O'Sullivan M, et al. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med. 2007;13(9):1060-1069. (Pubitemid 47517503)
34. Huang Y, De Reynies A, De Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal-type. Blood. 2010;115(6):1226-1237.
35. Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood. 2009;113(20):4918-4921.
36. Hibi K, Sakata M, Sakuraba K, et al. Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer. Anticancer Res. 2008;28(3A):1581-1584. (Pubitemid 351892933)
37. Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004;5(10):1052-1060. (Pubitemid 41057725)
38. Wertz IE, O'Rourke KM, Zhou H, et al. Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430(7000):694-699. (Pubitemid 39061687)
39. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
40. Coppo P, Gouilleux-Gruart V, Huang Y, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia. 2009;23(9):1667-1678.
41. Chow C, Liu AY, Chan WS, Lei KI, Chan WY, Lo AW. AKT plays a role in the survival of the tumor cells of extranodal NK/T-cell lymphoma, nasal type. Haematologica. 2005;90(2):274-275. (Pubitemid 40293300)
42. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700-2707. (Pubitemid 46482061)
43. Anglesio MS, Evdokimova V, Melnyk N, et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet. 2004;13(18):2061-2074. (Pubitemid 39377829)
44. Sakata M, Kitamura YH, Sakuraba K, et al. Methylation of HACE1 in gastric carcinoma. Anticancer Res. 2009;29(6):2231-2233.
45. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 2009;15(3):752-757.
46. Zou Y, Tsai WB, Cheng CJ, et al. Forkhead box transcription factor FOXO3a suppresses estrogen- dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res. 2008; 10(1):R21.
47. Paik JH, Kollipara R, Chu G, et al. FoxOs are lineage- restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007; 128(2):309-323. (Pubitemid 46123514)
48. So CW, Cleary ML. Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood. 2003;101(2):633-639. (Pubitemid 36077587)
49. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell. 1994;77(2):297-306. (Pubitemid 24138626)
50. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107(10):4090-4100. (Pubitemid 43726818)
51. Fearon E. Tumor-suppressor genes. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York: McGraw Hill; 2002:197-206.